Skip to main content
. 2018 Sep 12;67(10):1477–1492. doi: 10.1093/cid/ciy585

Table 2.

Drug Interactions Between Direct-acting Antivirals and Antiretroviral Drugs—Preferred Regimens

graphic file with name ciy58501.jpg

Green indicates coadministration is safe; yellow indicates a dose change or additional monitoring is warranted; and pink indicates the combination should be avoided.

Abbreviation: ND, no data.

aCaution only with tenofovir disoproxil fumarate.

bIncrease in tenofovir depends on which additional concomitant antiretroviral agents are administered.

cAvoid tenofovir disoproxil fumarate in patients with an estimated glomerular filtration rate <60 mL/min; tenofovir concentrations may exceed those with established renal safety data in individuals on ritonavir- or cobicistat-containing regimens.

dStudied as part of fixed-dose combinations with ledipasvir/sofosbuvir or sofosbuvir/velpatasvir plus TAF, emtricitabine, elvitegravir, and cobicistat.